NewEdge Advisors LLC Purchases 6,252 Shares of IQVIA Holdings Inc. $IQV

NewEdge Advisors LLC increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 21.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,368 shares of the medical research company’s stock after buying an additional 6,252 shares during the quarter. NewEdge Advisors LLC’s holdings in IQVIA were worth $6,032,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of IQV. Financial Freedom LLC purchased a new stake in IQVIA in the 1st quarter worth approximately $25,000. Ascentis Independent Advisors bought a new stake in IQVIA in the 1st quarter worth approximately $25,000. International Assets Investment Management LLC purchased a new stake in IQVIA during the fourth quarter valued at $27,000. Gilpin Wealth Management LLC purchased a new position in IQVIA in the fourth quarter worth about $27,000. Finally, CrossGen Wealth LLC bought a new position in shares of IQVIA during the 4th quarter valued at approximately $28,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on IQV shares. TD Cowen boosted their target price on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. upped their price target on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Robert W. Baird boosted their price objective on shares of IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Finally, Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $242.23 on Tuesday. The firm has a 50 day moving average of $202.03 and a 200 day moving average of $186.65. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $39.87 billion, a price-to-earnings ratio of 30.05, a price-to-earnings-growth ratio of 2.03 and a beta of 1.18. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $251.36.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter last year, the firm earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its board has initiated a stock buyback program on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In other news, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider directly owned 2,989 shares in the company, valued at approximately $732,932.69. The trade was a 15.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 12,913 shares of company stock worth $3,098,793 over the last ninety days. 1.70% of the stock is currently owned by company insiders.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.